How should we best target the biology of ER PR HER2 negative breast cancer?

被引：0
|
作者：
Tutt, A. N. J. [1 ]
Reis-Filho, J. S. [2 ]
机构：
[1] Kings Coll London, Breakthrough Breast Canc Res Unit, London WC2R 2LS, England
[2] Inst Canc Res, Breakthrough Breast Canc Res Ctr, London SW3 6JB, England
来源：
EJC SUPPLEMENTS | 2008年 / 6卷 / 07期
关键词：
D O I：
10.1016/S1359-6349(08)70703-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：166 / 166
页数：1
相关论文
共 50 条
  • [31] Evaluation of ER, PR and HER2 markers by flow cytometry for breast cancer diagnosis and prognosis
    Wopereis, Sandro
    Walter, Laura Otto
    Couto Vieira, Daniella Serafin
    Biasi Ribeiro, Amanda Abdalla
    Fernandes, Braulio Leal
    Wilkens, Renato Salerno
    Santos-Silva, Maria Claudia
    CLINICA CHIMICA ACTA, 2021, 523 : 504 - 512
  • [32] The discordance of the ER, PR, and HER2 status after neoadjuvant chemotherapy in breast cancer.
    Ustaalioglu, Basak Oven
    Bilici, Ahmet
    Aker, Fugen Vardar
    Erkol, Burcak
    Aliustaoglu, Mehmet
    Gurleyik, Gunay
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [33] Biology of HER2 and its importance in breast cancer
    Yarden, Y
    ONCOLOGY, 2001, 61 : 1 - 13
  • [34] HER2 POSITIVE BREAST CANCER - BIOLOGY AND RESISTANCE
    Penault-Llorca, Frederique
    BREAST, 2019, 48 : S31 - S31
  • [35] Activating HER2 Mutations in HER2 Gene Amplification Negative Breast Cancer
    Bose, Ron
    Kavuri, Shyam M.
    Searleman, Adam C.
    Shen, Wei
    Shen, Dong
    Koboldt, Daniel C.
    Monsey, John
    Goel, Nicholas
    Aronson, Adam B.
    Li, Shunqiang
    Ma, Cynthia X.
    Ding, Li
    Mardis, Elaine R.
    Ellis, Matthew J.
    CANCER DISCOVERY, 2013, 3 (02) : 224 - 237
  • [36] Breast Cancer Biomarker Changes and Correlations with HER2 Change in ER Positive, HER2 Negative Breast Cancers Treated with Neoadjuvant Endocrine Therapy
    Huang, Wei
    Tyburski, Haley
    Finkelman, Brian
    Turner, Bradley
    Weiss, Anna
    Dhakal, Ajay
    Skinner, Kristin
    Hicks, David
    Zhang, Huina
    LABORATORY INVESTIGATION, 2024, 104 (03) : S175 - S176
  • [37] Discordance of the ER, PR, and Her2 Receptors in the neoadjuvant pretreated Breast Carcinoma
    Kreklau, A.
    Nel, I
    Weydandt, L.
    Aktas, B.
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2021, 81 (06) : E45 - E45
  • [38] Synthetic lethal strategies in ER/HER2 negative breast cancers
    Tutt, A.
    EJC SUPPLEMENTS, 2010, 8 (03): : 185 - 185
  • [39] THE CONCORDANCE AND BUDGET IMPACT OF MULTIPLE ER, PR AND HER2 DETERMINATIONS IN DUTCH BREAST CANCER PATIENTS
    Berghuis, A. S.
    Koffijberg, H.
    van Deurzen, C.
    Sleijfer, S.
    Terstappen, L. W.
    IJzerman, M.
    VALUE IN HEALTH, 2018, 21 : S247 - S248
  • [40] Profile changing of ER, PR, HER2 between primary tumour and locoregional metastases in breast cancer
    Rais, A.
    Houcine, Y.
    Kamoun, S.
    Alaya, M.
    Driss, M.
    VIRCHOWS ARCHIV, 2024, 485 : S202 - S203
12345